Singh, 2020 - Google Patents
Role of Focused Ultrasound in CD40 Mediated Anti-Tumor ImmunitySingh, 2020
View PDF- Document ID
- 2302026490544635617
- Author
- Singh M
- Publication year
External Links
Snippet
Advanced stage melanoma tumors are chemo-and radio-resistant, demonstrate poor antigenicity and defective antigen presentation mechanisms, and low tumor specific cytotoxic T cell population, resulting in poor survival rates in patients. Novel therapeutic …
- 230000036039 immunity 0 title abstract description 62
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation; Therapies using these preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Medrano et al. | Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy | |
| Gough et al. | Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice | |
| Liu et al. | Injectable supramolecular hydrogel for locoregional immune checkpoint blockade and enhanced cancer chemo-immunotherapy | |
| AU2020291109A1 (en) | Compositions and methods for subcutaneous administration of cancer immunotherapy | |
| KR20200046065A (en) | Combination immunotherapy and cytokine control therapy to treat cancer | |
| JP2019506438A (en) | SMC combination therapy for the treatment of cancer | |
| US10071118B2 (en) | Compositions and methods for treating peritoneal cancers | |
| Kim et al. | TLR7/8 agonist-loaded nanoparticles augment NK cell-mediated antibody-based cancer immunotherapy | |
| WO2019136305A1 (en) | Cell-based and immune checkpoint inhibitor therapies combined with il-12 for treating cancer | |
| CN110520438A (en) | Oncolytic viral therapy | |
| Shen et al. | Tailoring chemoimmunostimulant bioscaffolds for inhibiting tumor growth and metastasis after incomplete microwave ablation | |
| Yu et al. | Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma | |
| US10597731B2 (en) | Allogeneic autophagosome-enriched composition for the treatment of disease | |
| Ding et al. | A TLR5 agonist enhances CD8+ T cell-mediated graft-versus-tumor effect without exacerbating graft-versus-host disease | |
| Xu et al. | Activatable immunoprotease nanorestimulator for second near-infrared photothermal immunotherapy of cancer | |
| Buteyn et al. | Activation of the intracellular pattern recognition receptor NOD2 promotes acute myeloid leukemia (AML) cell apoptosis and provides a survival advantage in an animal model of AML | |
| James et al. | Effective TRAIL-based immunotherapy requires both plasmacytoid and CD8α dendritic cells | |
| Ghosh et al. | Immune checkpoint blockade enhances chemophototherapy in a syngeneic pancreatic tumor model | |
| Luly et al. | Biomaterial-mediated genetic reprogramming of Merkel Cell Carcinoma and Melanoma leads to targeted Cancer Cell Killing in Vitro and in vivo | |
| CN118542841A (en) | Immunomodifying particles for the treatment of cancer | |
| Chen et al. | Chimeric peptide engineered bioregulator for metastatic tumor immunotherapy through macrophage polarization and phagocytosis restoration | |
| Singh | Role of Focused Ultrasound in CD40 Mediated Anti-Tumor Immunity | |
| Wang et al. | Dual-Responsive Epigenetic Inhibitor Nanoprodrug Combined with Oncolytic Virus Synergistically Boost Cancer Immunotherapy by Igniting Gasdermin E-Mediated Pyroptosis | |
| US20210169979A1 (en) | System and method for sonosensitized cancer immunotherapy with nanoparticles | |
| JP7334249B2 (en) | Early apoptotic cells for use in treating sepsis |